The results of the European Parliamentary elections in the UK point to a divided country. However, the recently formed Brexit Party has secured a significant vote at the Conservative Party’s expense. Now, as the Conservative Party seeks to regroup and select a new leader, the likelihood of a ‘no deal’ exit has further increased. The seventh Acorn Regulatory Brexit whitepaper looks at the impact of a no-deal Brexit departure from the EU on a number of sectors. Our pharmacovigilance team looks at the measures that companies need to put in place now if they are to prepare for the UK leaving the EU without a deal. The role of the QPPV has been much discussed in recent years, since the outcome of the referendum became known, and companies need to be aware of the implications that Brexit will have on that role. The medical devices team look at the role of the EU Authorised Representative and the implications for Notified Bodies. The devices sector is in a particular ‘state of flux’ at present with the introduction of new legislation and Brexit adds to the issues that device manufacturers need to be mindful of at this time. Finally, our medical team look at the impact on clinical trials. Trial sponsors and partners need to be aware of the impact of Brexit and the article contained in the whitepaper looks at what needs to be considered. You can download the latest Acorn Regulatory Brexit whitepaper by completing the details below and we will send it straight to you. [ninja_form id=52] We have also produced further Brexit publications, including: Is Time Running Out? was published in 2018 Heading for the Exit was published in Q4 2016. The Implications of Brexit was published in Q3 2016 As the thought leaders on the Brexit issue in the regulatory affairs sector we have also produced a number of articles relating to the UK’s decision to leave the EU. You can read more HERE.